This clinical trial is focused on studying treatments for Multiple Myeloma, a type of cancer that affects plasma cells in the bone marrow. The study will compare two treatment approaches for patients who are newly diagnosed and eligible for a stem cell transplant. The first approach involves a combination of medications: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (referred to as DVRd), followed by a treatment called Ciltacabtagene Autoleucel, which is a type of cell therapy. The second approach uses the same combination of medications (DVRd) followed by an Autologous Stem Cell Transplant (ASCT), where a patient’s own stem cells are used to help restore healthy bone marrow.

The purpose of the study is to compare the effectiveness of these two treatment strategies. Participants will receive either the DVRd treatment followed by Ciltacabtagene Autoleucel or the DVRd treatment followed by ASCT. The study will monitor the progress of the disease and the response to treatment over time. Participants will be closely observed to see how well the treatments work in controlling the disease and maintaining remission, which means the cancer is not active.

Throughout the study, participants will receive regular medical check-ups and assessments to ensure their safety and to track the effectiveness of the treatments. The study aims to provide valuable information on which treatment approach may offer better outcomes for patients with newly diagnosed Multiple Myeloma. Participants will be randomly assigned to one of the two treatment groups, and some may receive a placebo as part of the study design. The trial is expected to continue for several years to gather comprehensive data on the long-term effects and benefits of the treatments being studied.